PharmaTelevision - The credit crunch as an opportunity: A deal maker's paradise?

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: The credit crunch as an opportunity: A deal maker's paradise?

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

What are the deal making implications of the credit crunch? This discussion takes a look at the impact of market conditions on biotechs'/VCs'/large pharma's current business and future prospects, liquidity and availability of finance, the impact on pipelines, availability of suitable programmes for large and mid sized pharma and biotech and the impact on valuations on distressed and acquiring companies.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

The changes in deal making.

Fintan Walton:

Welcome to the, our first panel discussion today at our exceptional meeting here at the British Consulate in Cambridge, Boston. On my panel I am very pleased to have three distinguish guests representing different parts of the industry. If I can start at the extreme right hand side - my left we've got Todd Maclaughlan who currently heads up Negotiations for Novartis Oncology, welcome Todd. Next to him I have Stephen Potter, who is Senior Vice President in Corporate and Business Development for Genzyme, welcome Stephen Potter.

Stephen Potter:

Thank you.

Fintan Walton:

And another distinguish guest Rob Wills from Johnson & Johnsonand he holds the position of Vice President Alliance Management at Johnson & Johnson. So, so welcome to the panel, three of you.

Rob Wills:

Thank you.

Fintan Walton:

Now we are here to talk about deal making during the financial crisis. So the very first question is I ask you Rob Wills, man who is out there doing deals and helping deals coming along has there been a change in the way deal making is taking place in the last 12 months, have we seen a significant change?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Todd Maclaughlan

Head of Negotiations

Rob Wills, is the VP Alliance Management at Johnson & Johnson. Stephen Potter, is presently the SVP Corporate Development at Genzyme. Todd Maclaughlan, is positioned as Head of Negotiations, Oncology Novartis.

Johnson & Johnson

Johnson & Johnson has been a part of people's lives for more than 120 years and a valuable part of their investments for more than 60 years. Founded in 1886, we listed our shares on the New York Stock Exchange for public investors in 1944. During our history, we have built the most comprehensive base of health care businesses in the world, generating more than 70 percent of our revenues from No. 1 or No. 2 global leadership positions in our respective markets. Our consistent performance has enabled us to deliver an exceptional track record of growth that few, if any, companies can claim: 76 consecutive years of sales increases; 25 consecutive years of adjusted earnings increases; and 47 consecutive years of dividend increases. Genzyme One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 12,000 employees in locations spanning the globe and 2008 revenues of $4.6 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. With many established products and services helping patients in nearly 100 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. Novartis We believe our portfolio best meets the varied and often complex needs of patients and societies. Novartis is positioned to lead in innovation, partner with others and offer solutions to patients across a broad healthcare spectrum. In addition, a diverse portfolio reduces financial risk, bringing greater value to those who invest in our company. Novartis has been transformed since its creation in 1996 - when only 45% of net sales came from healthcare - into a leader focused on fast-growing areas of healthcare.